Back
Nimesh Pinnamaneni
•
Helixworks Technologies • 6m
Why qPCR & phenotypic testing must be displaced? - Part I The Problem: Infectious diseases remain a significant public health threat. Particularly, in low and middle-income countries (LMICs), such as India. €300 Billion / 27 Trillion INR! {1} - That’s the yearly economic impact of just one disease (TB) in India, Africa and Brazil. - Determining the right treatment for infectious diseases can take anywhere from 7 to 50 days, requiring multiple lab visits as doctors try to build a complete picture. - The current cycle of prescribing without clear diagnosis fuels Anti Microbial Resistance (AMR). It is one of the most pressing global health challenges, at our doorstep. Currently, a combination of qPCR and phenotypic testing is the gold standard for diagnosing drug resistance. - However, this approach is both time-consuming and limited in scope. The delay not only prolongs patient suffering but also contributes to the misuse of antibiotics. - The misuse and overuse of antibiotics have accelerated the emergence of drug-resistant pathogens. - The WHO estimates that AMR currently causes at least 700,000 deaths per year worldwide, a number that could rise to 10 million by 2050 if no action is taken. You might be asking, is there a more efficient way to address this problem? Imagine if we could eliminate the guesswork from prescribing treatments right from the first visit... Picture this: with just one sample, during a single clinic visit, clinicians receive a detailed report that not only identifies the infection but also provides a complete drug resistance profile. - This would allow them to make informed, data-driven decisions and prescribe the right antibiotics immediately. - Such an advancement could revolutionise how we combat the escalating threat of antimicrobial resistance. Imagine diagnosing infections and drug resistance in ONE clinic visit. I’m working on it—reply with your thoughts or follow for updates! {1} https://www.medscape.com/viewarticle/tuberculosis-prevention-brings-economic-gains-says-who-2024a10006h9?form=fpf {2} (https://cdn.who.int/media/docs/default-source/documents/no-time-to-wait-securing-the-future-from-drug-resistant-infections-en.pdf?sfvrsn=5b424d7_6&download=true)
More like this
Recommendations from Medial
Nimesh Pinnamaneni
•
Helixworks Technologies • 6m
Why qPCR & Phenotypic Testing Must Be Displaced – Part II If you ever want to understand the scale of a problem, look at how much it costs. Tuberculosis alone costs India, Africa, and Brazil 27 trillion INR a year in lost productivity and healthcare
See More
Nimesh Pinnamaneni
•
Helixworks Technologies • 6m
Can Sequencing replace traditional diagnostics in India? Traditional diagnostics are slow. Culture and antibiotic resistance tests take days or even weeks to deliver results. This can be detrimental for patients suffering from sepsis or fever of unk
See More
Nimesh Pinnamaneni
•
Helixworks Technologies • 6m
Why qPCR & Phenotypic Testing Must Be Displaced? – Part III This is the third part of a deep dive into why qPCR & phenotypic testing need to be replaced. In Part I, I covered the limitations of current diagnostics & why incremental improvements aren
See More
Yogesh Borse
"Empowering Healthca... • 8m
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a revolutionary genetic engineering tool that allows scientists to edit DNA with unprecedented precision, efficiency, and flexibility. It is based on a natural defense mechanism fo
See More
Dr Bappa Dittya Saha
We're gonna extinct ... • 5m
“Think in Systems, Not Symptoms” 1. The Problem With Symptom-Based Thinking Traditional medicine often works like this: Symptom → Diagnosis → Drug If tired: Rule out anaemia, hypothyroid, depression. If bloated: Rule out IBS, lactose intolerance,
See More
Download the medial app to read full posts, comements and news.